VelosBio Emerges with $58M in Funding to Steer Cancer Drugs to Clinic
Xconomy
OCTOBER 1, 2018
VelosBio joined Johnson & Johnson’s JLABS @ San Diego incubator in January. The company is developing antibody drug conjugates, a class of cancer drug that links antibodies to potent cancer-fighting toxins. The new VelosBio cash, a Series A round of financing, was led by Arix Bioscience (LSE: ARIX ) and Sofinnova Ventures.
Let's personalize your content